Biosimilar Tracking Still Possible With Shared Medicare Codes, Woodcock Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and CMS are working on a way to address pharmacovigilance through code modifiers, CDER director tells Senate panel.